RayKnowChina Research Map
Shortlist0

ShanghaiFudan University

Fudan University Shanghai Cancer Center

复旦大学附属肿瘤医院

Listed for 10 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Fudan University Shanghai Cancer Center

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌38 papers led1 open trial led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌32 papers led8 open trials led
  3. Hepatocellular carcinoma肝细胞癌54 papers led2 open trials led
  4. Stomach cancer胃癌88 papers led17 open trials led
  5. Chordoma脊索瘤3 papers led
  6. Osteosarcoma骨肉瘤6 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  8. Ewing sarcoma尤文肉瘤4 papers led
  9. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  10. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Hepatoblastoma, Retinoblastoma, Neuroblastoma, Multiple myeloma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 38 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.6%.

Papers led
38
2021–2025
Trials led
15
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 5520212022: 7720222023: 8820232024: 121220242025: 662025

10 hospitals in Shanghai for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
    Phase
    Phase 3
    Started
    2023-12
    Registry
    NCT06177301

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  2. Recruiting
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Registry
    NCT07258979

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen

  3. Recruiting
    Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07303023

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Chongqing, Hangzhou, Shanghai

  4. Recruiting
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06308328

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai

  5. Recruiting
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06437522

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  6. Recruiting
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05340491

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  7. Recruiting
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    Phase
    Phase 3
    Started
    2020-03
    Registry
    NCT03907826

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  8. Not yet recruiting
    Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04215510

    Age 18 years to 70 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 3 listed hospitals as study sitesFuzhou, Nanchang, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseInduction / concurrent chemotherapy
Departments in papersRadiation oncologyRadiology / nuclear medicine
Papers it led38
  1. Autophagy-dependent sensitization effects of PARP inhibitors on recurrent nasopharyngeal carcinoma treated with carbon ion and photon irradiation.2025Acta biochimica et biophysica SinicaFree full text
  2. RAC2 drives hypoxia-mediated radiation resistance in nasopharyngeal carcinoma.2025Biochemical and biophysical research communications
  3. Pretreatment FDG PET in prognosis of locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.2025International journal of medical sciencesFree full text
  4. Long-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults.2025Journal of cancer research and clinical oncologyFree full text
  5. The role of 18 F-FDG PET/CT in detecting recurrence and metastasis in posttreatment nasopharyngeal carcinoma patients with elevated Epstein-Barr virus DNA.2025Nuclear medicine communications
  6. Beyond the ratio of tumor reduction: residual volume after induction chemotherapy emerges as the optimal biomarker in advanced nasopharyngeal cancer.2025Radiation oncology (London, England)Free full text
  7. Comparing long-term efficacy and safety of GP versus TPF sequential chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.2024BMC cancerFree full text
  8. Long-term outcomes after particle radiation therapy in patients with nasopharyngeal adenoid cystic carcinoma.2024BMC cancerFree full text
  9. Deletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non-metastatic stage T4 nasopharyngeal carcinoma in IMRT era.2024Cancer medicine
  10. A protocol for a randomized trial evaluating the role of carbon-ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma.2024Cancer medicineFree full text
  11. PICK1 inhibits the malignancy of nasopharyngeal carcinoma and serves as a novel prognostic marker.2024Cell death & diseaseFree full text
  12. Radiation-induced nasopharyngeal ulcers after re-irradiation with intensity-modulated radiotherapy in locoregional recurrent nasopharyngeal carcinoma patients: a dose-volume-outcome analysis.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  13. Nomograms containing body dose parameters for predicting survival in patients with nasopharyngeal carcinoma.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck SurgeryFree full text
  14. Liquid biopsy with plasma Epstein-Barr virus DNA characterizes biological relapse for the prediction of cancer recurrence in non-disseminated nasopharyngeal carcinoma.2024European journal of cancer (Oxford, England : 1990)
  15. Survival outcomes and toxicity profiles among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) versus IMRT + carbon-ion radiotherapy: A propensity score-matched analysis.2024Head & neck
  16. Delta magnetic resonance imaging radiomics features‑based nomogram predicts long‑term efficacy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.2024Oral oncology
  17. Tumor volume instead of recurrent T category predicts clinical outcome of patients with locally recurrent nasopharyngeal carcinoma salvaged by carbon ion radiation therapy.2024Oral oncology
  18. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.2024Signal transduction and targeted therapyFree full text
  19. Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  20. Multi-task deep learning-based radiomic nomogram for prognostic prediction in locoregionally advanced nasopharyngeal carcinoma.2023European journal of nuclear medicine and molecular imagingFree full text
  21. Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes.2023Oral oncology
  22. Unraveling the patterns and pathways of local recurrence of nasopharyngeal carcinoma: evidence for individualized clinical target volume delineation.2023Radiation oncology (London, England)Free full text
  23. Induction chemotherapy plus re-irradiation versus re-irradiation alone in locally recurrent nasopharyngeal carcinoma: A model-based analysis.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  24. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  25. Trajectories of fear of progression in nasopharyngeal carcinoma patients receiving proton and heavy ion therapy.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  26. A qualitative exploration of fear of progression in patients with nasopharyngeal carcinoma treated with proton and heavy ion therapy.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  27. Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck SurgeryFree full text
  28. Hepatic resection prolongs overall survival in the selected patients with nasopharyngeal carcinoma liver metastases.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  29. Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era.2022International journal of medical sciencesFree full text
  30. Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment.2022Journal of experimental & clinical cancer research : CRFree full text
  31. Dissecting the heterogeneity of the microenvironment in primary and recurrent nasopharyngeal carcinomas using single-cell RNA sequencing.2022OncoimmunologyFree full text
  32. Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma.2022Oral oncology
  33. Predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma survivors after intensity-modulated radiotherapy.2022Radiation oncology (London, England)Free full text
  34. Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma.2021Annals of nuclear medicine
  35. Long-Term Results of Intensity-Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma: New Insight into the Value of Concurrent Chemotherapy.2021Cancer investigation
  36. Clinical characteristics and prognosis of elderly nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck SurgeryFree full text
  37. Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?2021Frontiers in immunologyFree full text
  38. Survival impact of increasing time to IMRT initiation following induction chemotherapy in nasopharyngeal carcinoma: A propensity score-matched analysis.2021Oral oncology
All its trials on ClinicalTrials.gov, any status34
  1. Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPCRecruitingNCT06177301Lead (inferred)Phase 3Start 2023-12
  2. Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver MetastasesStatus unknownNCT05771025Lead (inferred)N/AStart 2023-04
  3. SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04351282Lead (inferred)N/AStart 2020-06
  4. Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPCStatus unknownNCT03366415Lead (inferred)Phase 3Start 2018-01
  5. Radiation-associated Carotid Artery Disease in Patients With Nasopharyngeal CarcinomaStatus unknownNCT03568032Lead (inferred)Start 2018-07
  6. S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaCompletedNCT03668366Lead (inferred)Phase 2Start 2013-08
  7. Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPCCompletedNCT02012062Lead (inferred)Phase 3Start 2012-07
  8. Treatment of Cerebral Radiation Necrosis With GM1, a Prospective StudyStatus unknownNCT01884987Lead (inferred)Start 2012-01
  9. SOX as Salvage Treatment in Nasopharyngeal CarcinomaTerminatedNCT01403259Lead (inferred)Phase 2Start 2011-07
  10. Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal CancerStatus unknownNCT01614938Lead (inferred)Phase 2Start 2010-08
  11. Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal CarcinomaCompletedNCT03389295Lead (inferred)Phase 2Start 2010-01
  12. Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)Status unknownNCT00817583Lead (inferred)Phase 2Start 2009-01
  13. Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal CarcinomaStatus unknownNCT00816816Lead (inferred)Phase 2Start 2007-02
  14. Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal CarcinomaStatus unknownNCT00817258Lead (inferred)Phase 2Start 2007-01
  15. Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal CarcinomaStatus unknownNCT00816855Lead (inferred)Phase 2Start 2007-02
  16. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  17. Individualized Neck Cervical Irradiation Prophylaxis Trial of NPCRecruitingNCT07303023Study sitePhase 3Start 2025-09
  18. A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT06437522Study sitePhase 2Start 2024-06
  19. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT06308328Study siteStart 2024-04
  20. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Study sitePhase 3Start 2022-04
  21. Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRTNot yet recruitingNCT04215510Study sitePhase 3Start 2021-03
  22. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Study sitePhase 3Start 2020-03
  23. Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)TerminatedNCT05721222Study sitePhase 1/Phase 2Start 2023-03
  24. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  25. A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal CarcinomaCompletedNCT03866967Study sitePhase 2Start 2019-03
  26. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
  27. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
  28. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  29. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02633176Study sitePhase 3Start 2015-01
  30. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02944708Study sitePhase 3Start 2015-10
  31. Neurological Effects of Acupuncture to Prevent Radiation-induced XerostomiaCompletedNCT02292368Study siteN/AStart 2014-11
  32. Xerostomia Pilot Fudan: Acupuncture for Prevention of Radiation-Induced XerostomiaStatus unknownNCT00862550Study siteN/AStart 2009-03
  33. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerStatus unknownNCT01074021Study sitePhase 3Start 2009-10
  34. Acupuncture for Prevention of Radiation-Induced XerostomiaCompletedNCT00430378Study siteN/AStart 2007-01
More papers found outside PubMed (not counted)45
  1. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncologyarticle
  2. 708P A single-arm, multicenter, prospective phase II study of tislelizumab in combination with nimotuzumab and GP induction followed by IMRT and tislelizumab plus nimotuzumab for high-risk locally advanced nasopharyngeal carcinoma (Recent D2025Annals of Oncologyarticle
  3. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncologyarticle
  4. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  5. CACA guidelines for holistic integrative management of adolescent and childhood nasopharyngeal carcinoma2025Holistic Integrative Oncologyarticle
  6. LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv2025Annals of Oncologyconference-abstract
  7. Management for Local or Regional Recurrent Nasopharyngeal Cancer2025Medical radiologybook-chapter
  8. Systemic Treatment for Metastatic Nasopharyngeal Carcinoma2025Medical radiologybook-chapter
  9. TransPred: A Novel 3D Deep Learning Model for Predicting Recurrence Risk of Nasopharyngeal Cancer after Radiotherapy2025International Journal of Radiation Oncology*Biology*Physicsarticle
  10. WITHDRAWN: 1373P Preliminary result of an open-label, single-arm, multicenter phase II study on tislelizumab combined with TP regimen induction chemotherapy followed by concurrent chemoradiotherapy with IMRT + IMCT for locally advanced naso2025Annals of Oncologyretraction
  11. WITHDRAWN: 1387P Deciphering tumor heterogeneity in advanced nasopharyngeal carcinoma (stage IVA): integrative analysis of dynamic EBV-DNA fluctuations and clinical outcomes2025Annals of Oncologyretraction
  12. WITHDRAWN: 1440TiP Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine(GX) versus tislelizumab plus gemcitabine/cisplatin(GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multic2025Annals of Oncologyretraction
  13. 847O Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial2024Annals of Oncologyarticle
  14. Efficacy of nimotuzumab added to concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  15. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncologyconference-abstract
  16. Identifying patients at high risk of recurrence by rebound of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  17. PATTERN OF TREATMENT FAILURE AMONG PATIENTS WITH RECURRENT NASOPHARYNGEAL CARCINOMA AFTER CARBON ION RE-IRRADIATION2024International Journal of Particle Therapyarticle
  18. Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.2024Journal of Clinical Oncologyconference-abstract
  19. 718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies2023Journal for ImmunoTherapy of Cancerconference-abstract
  20. A MRI-based radiomics combined prediction model for radiation-induced temporal lobe injury in nasopharyngeal carcinoma patients2023Journal of Radiation Research and Applied Sciencesarticle
  21. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncologyarticle
  22. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncologyconference-abstract
  23. Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies2023The Oncologistarticle
  24. Prognostic Value of Lymph Node-to-Primary Tumor Ratio of PET Standardized Uptake Value for Nasopharyngeal Carcinoma: A Recursive Partitioning Risk Stratification Analysis2023International Journal of Radiation Oncology*Biology*Physicsarticle
  25. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.2023Journal of Clinical Oncologyconference-abstract
  26. Radiotherapy Alone vs. Concurrent or Adjuvant Chemoradiotherapy for Nasopharyngeal Carcinoma Patients with Negative Epstein-Barr Virus DNA Post-Induction Chemotherapy2023International Journal of Radiation Oncology*Biology*Physicsarticle
  27. Radiotherapy alone versus concurrent or adjuvant chemoradiotherapy for nasopharyngeal carcinoma patients with negative Epstein-Barr virus DNA post-induction chemotherapy.2023Journal of Clinical Oncologyconference-abstract
  28. Response-adapted therapy for locally advanced nasopharyngeal carcinoma based on clinical response and circulating Epstein-Barr virus DNA level post induction chemotherapy.2023Journal of Clinical Oncologyconference-abstract
  29. 226MO Is induction chemotherapy beneficial in locally recurrent nasopharyngeal carcinoma before re-irradiation? A multicenter retrospective analysis2022Annals of Oncologyarticle
  30. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Researchconference-abstract
  31. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset
  32. Anatomic distribution of local recurrence of nasopharyngeal carcinoma in the Era of IMRT: Suggestion of modification of clinical target volume delineation.2022Journal of Clinical Oncologyconference-abstract
  33. Clinical characteristics and long-term outcomes of individualized re-treatment in locoregionally recurrent nasopharyngeal carcinoma2022Research Squarepreprint
  34. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncologyconference-abstract
  35. Tislelizumab Rechallenge for Recurrent or Metastatic Nasopharyngeal Carcinoma (RM-NPC) Previously Treated with Another Anti-PD1 Antibody2022International Journal of Radiation Oncology*Biology*Physicsarticle
  36. Value of pretreatment 18F-FLT PET/CT and 18F-FDG PET/CT uptake heterogeneity for early prediction of treatment outcome in locally advanced nasopharyngeal carcinoma2022DOAJ (DOAJ: Directory of Open Access Journals)article
  37. Willis Covered Stent Implantation for Treating Radiation Internal Carotid Blowout Syndrome in Nasopharyngeal Carcinoma2022Frontiers in Medical Case Reportsarticle
  38. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncologyarticle
  39. A Novel Machine Learning-Derived Radiomic Signature Predictive of Nasopharyngeal Necrosis to Guide Re-Radiotherapy for Recurrent Nasopharyngeal Carcinoma: A Multicentre Study2021SSRN Electronic Journalpreprint
  40. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncologyconference-abstract
  41. Combining Images and T-Staging Information to Improve the Automatic Segmentation of Nasopharyngeal Carcinoma Tumors in MR Images2021IEEE Accessarticle
  42. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncologyconference-abstract
  43. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset
  44. New Developments in the Management of Nasopharyngeal Carcinoma2021Springer eBooksbook-chapter
  45. The Dosimetric Impact of Deep Learning-Based Auto-Segmentation of Organs at Risk on Nasopharyngeal and Rectal Cancer2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 32 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
32
2021–2025
Trials led
28
any status, ClinicalTrials.gov
Open trials led
8
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 6620212022: 5520222023: 8820232024: 6620242025: 772025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07403136

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  2. Recruiting
    PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07697859

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  3. Recruiting
    CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06964568

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  4. Recruiting
    TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06676449

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  5. Recruiting
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05443841

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou

  6. Recruiting
    Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT06190782

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  7. Recruiting
    Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT04522687

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  8. Not yet recruiting
    A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06152978

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  9. Not yet recruiting
    Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07769658

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou University; 5 listed hospitals as study sitesChengdu, Guangzhou, Kunming, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentRadiotherapyImmunotherapy
Departments in papersRadiation oncologyMedical oncologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led32
  1. Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study.2025Cancer immunology, immunotherapy : CIIFree full text
  2. Radiation-induced extracellular vesicles from cancer-associated fibroblasts drive oesophageal squamous cell carcinoma metastasis via the miR-193a-3p/PTEN/Akt pathway.2025Clinical and translational medicineFree full text
  3. Neoadjuvant chemoimmunotherapy cycles in locally advanced Esophageal squamous cell carcinoma: a retrospective comparison of three versus two cycles.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  4. Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial2025International journal of cancerRCT
  5. Coptisine inhibits esophageal carcinoma growth by modulating pyroptosis via inhibition of HGF/c-Met signaling.2025Naunyn-Schmiedeberg's archives of pharmacology
  6. Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma.2025Signal transduction and targeted therapyFree full text
  7. Phase II trial of radiotherapy plus Huachansu in elderly or chemotherapy-ineligible patients with locally advanced esophageal squamous cell carcinoma.2025The oncologistRCTFree full text
  8. Postoperative Radiotherapy in Curatively Resected Esophageal Squamous Cell Carcinoma With Occult Recurrent Laryngeal Nerve Lymph Node Metastasis.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  9. Prognostic value of genomic mutation signature associated with immune microenvironment in southern Chinese patients with esophageal squamous cell carcinoma.2024Cancer immunology, immunotherapy : CIIFree full text
  10. The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma.2024Cancer letters
  11. Synaptotagmin 13 Could Drive the Progression of Esophageal Squamous Cell Carcinoma Through Upregulating ACRV1.2024DNA and cell biology
  12. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial.2024The lancet. Gastroenterology & hepatologyRCT
  13. Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis.2024Thoracic cancerFree full text
  14. Machine learning to predict occult metastatic lymph nodes along the recurrent laryngeal nerves in thoracic esophageal squamous cell carcinoma.2023BMC cancerFree full text
  15. Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis.2023Cancer medicineFree full text
  16. Caution against simultaneous integrated boost radiotherapy for upper thoracic esophageal squamous cell carcinoma: results from a single-arm phase II trial.2023Esophagus : official journal of the Japan Esophageal Society
  17. Precise pattern of lymphatic spread of esophageal squamous cell carcinoma: results of 1074 patients with N1 disease.2023Journal of cancer research and clinical oncologyFree full text
  18. Lymphocyte recovery from radiation-induced lymphopenia in locally advanced esophageal squamous cell carcinoma: correlations with prognosis and lymphocyte-related organs.2023Radiation oncology (London, England)Free full text
  19. Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9).2023Radiation oncology (London, England)Free full text
  20. Less Irradiation to Lymphocyte-Related Organs Reduced the Risk of G4 Lymphopenia in Esophageal Cancer: Re-Analysis of Prospective Trials.2023The oncologistFree full text
  21. Extracellular shuttling miR-21 contributes to esophageal cancers and human umbilical vein endothelial cell communication in the tumor microenvironment and promotes tumor angiogenesis by targeting phosphatase and tensinhomolog.2023Thoracic cancerFree full text
  22. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.2022JAMA network openRCTFree full text
  23. Dose escalation based on 18F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12).2022Radiation oncology (London, England)RCTFree full text
  24. PD-1 Inhibitor Enhanced Radiosensitivity by Reactivating T Cells and Inducing G2/M Phase Arrest in Esophageal Squamous Cell Carcinoma.2022Radiation research
  25. Potentially functional genetic variants of the notch signaling pathway genes predict survival of Chinese patients with esophageal squamous cell carcinoma.2022The journal of gene medicine
  26. Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study.2022The oncologistFree full text
  27. Impact of post-operative serum albumin level on anastomotic leakage after transthoracic oesophagectomy for oesophageal squamous cell carcinoma.2021ANZ journal of surgery
  28. Esophageal Carcinosarcoma: Analysis of Clinical Features and Prognosis of 24 Cases and a Literature Review.2021Cancer control : journal of the Moffitt Cancer CenterFree full text
  29. The superiority of [68Ga]-FAPI-04 over [18F]-FDG PET/CT in imaging metastatic esophageal squamous cell carcinoma.2021European journal of nuclear medicine and molecular imaging
  30. Local therapy for oligometastatic esophageal squamous cell carcinoma: a prospective, randomized, Phase II clinical trial.2021Future oncology (London, England)
  31. Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.2021International journal of radiation oncology, biology, physicsRCT
  32. A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11).2021The oncologistFree full text
All its trials on ClinicalTrials.gov, any status39
  1. Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic CancerRecruitingNCT04522687Lead sponsorStart 2012-01
  2. PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCCRecruitingNCT07697859Lead (inferred)Start 2026-07
  3. Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCCRecruitingNCT07403136Lead (inferred)Phase 2Start 2026-04
  4. CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCCRecruitingNCT06964568Lead (inferred)Phase 3Start 2025-02
  5. TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCCRecruitingNCT06676449Lead (inferred)Phase 3Start 2024-11
  6. A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06152978Lead (inferred)Phase 2Start 2023-12
  7. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)RecruitingNCT05443841Lead (inferred)Start 2022-07
  8. Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 InhibitorRecruitingNCT06190782Lead (inferred)Phase 3Start 2022-09
  9. A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.Status unknownNCT05760391Lead (inferred)N/AStart 2023-02
  10. Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)Status unknownNCT05281003Lead (inferred)Phase 2Start 2023-02
  11. TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06401447Lead (inferred)N/AStart 2023-12
  12. Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell CarcinomaStatus unknownNCT05633641Lead (inferred)Start 2022-10
  13. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Lead (inferred)Start 2021-10
  14. ctDNA-based MRD Assessment in Local Advanced Esophageal CarcinomaStatus unknownNCT05426850Lead (inferred)Start 2021-06
  15. Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)Active, not recruitingNCT04764227Lead (inferred)Phase 2Start 2020-05
  16. PET in Guiding Cervical Lymphadenectomy (ECTOP-2003)CompletedNCT03244566Lead (inferred)Start 2018-06
  17. Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell CarcinomasCompletedNCT03797625Lead (inferred)Phase 2Start 2017-05
  18. SIB in Upper Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04115618Lead (inferred)Phase 2Start 2017-01
  19. Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02677597Lead (inferred)Phase 3Start 2016-01
  20. Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell CarcinomasStatus unknownNCT02665702Lead (inferred)Phase 2Start 2016-01
  21. A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal CancerCompletedNCT02459457Lead (inferred)Phase 3Start 2015-07
  22. Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell CarcinomaStatus unknownNCT02384811Lead (inferred)Phase 2Start 2014-12
  23. Study of S-1 in Combination With Radiotherapy in Esophageal CancerCompletedNCT01831531Lead (inferred)Phase 2Start 2013-03
  24. A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal CarcinomaCompletedNCT01591135Lead (inferred)Phase 3Start 2012-04
  25. S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical StudyCompletedNCT01854749Lead (inferred)Phase 2Start 2011-11
  26. A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal CancerStatus unknownNCT01391572Lead (inferred)Phase 2Start 2011-04
  27. Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0Status unknownNCT01398449Lead (inferred)Phase 3Start 2011-04
  28. Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After EsophagectomyStatus unknownNCT01402180Lead (inferred)Phase 2/Phase 3Start 2010-12
  29. Standardized MRI and Structured Reporting for Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07769658Study siteStart 2026-09
  30. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCStatus unknownNCT05221658Study sitePhase 2Start 2022-08
  31. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  32. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  33. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  34. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  35. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  36. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  37. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  38. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  39. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09
More papers found outside PubMed (not counted)33
  1. 474. NEOADJUVANT CHEMOIMMUNOTHERAPY VERSUS CHEMOTHERAPY PLUS ESOPHAGECTOMY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: PRIMARY RESULT OF A RANDOMIZED CLINICAL TRIAL2025Diseases of the Esophagusarticle
  2. 475. COMPREHENSIVE GENOMIC AND TRANSCRIPTOMIC ANALYSES REVEAL PROGNOSTIC STRATIFICATION FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagusarticle
  3. 963P SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients (pts) with advanced or metastatic solid tumors: Results from dose escalation study2025Annals of Oncologyarticle
  4. Irradiated Tumor Cell-Derived Extracellular Vesicles Foster Immunosuppressive Macrophages Formation to Promote Esophageal Squamous Cell Carcinoma Progression2025International Journal of Radiation Oncology*Biology*Physicsarticle
  5. Medium dose of TPF chemotherapy with concurrent radiotherapy and immunotherapy for locally advanced esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyarticle
  6. Radiation-Induced Extracellular Vesicles from Cancer-Associated Fibroblasts Facilitate Esophageal Squamous Cell Carcinomametastasis through the miR-193a-3p/PTEN/Akt Pathway2025International Journal of Radiation Oncology*Biology*Physicsarticle
  7. The combination of PD-1 inhibitor with chemotherapy ± salvage chemoradiotherapy for local primary-recurrence esophageal squamous cell carcinoma after definitive chemoradiotherapy: A prospective, multicenter, single-arm clinical study (ESO-N2025Journal of Clinical Oncologyarticle
  8. 1462P A pilot study of hypoxia as a potential resistance mechanism to PD-1 checkpoint blockade therapy in neoadjuvant treatment of esophageal squamous cell carcinoma (HYPERION)2024Annals of Oncologyarticle
  9. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  10. Maximum PET/CT 18F-FDG uptake of lymph nodes predicts prognosis in esophageal squamous cell carcinoma2024International Journal of Radiation Researcharticle
  11. 145. PRECISE PATTERN OF LYMPHATIC SPREAD OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA RESULTS OF 1074 PATIENTS WITH N1 DISEASE2023Diseases of the Esophagusarticle
  12. A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  13. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figsharedataset
  14. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  15. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  16. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  17. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  18. Re-irradiation of In- or Out-of-PTV Esophageal Recurrence after Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma2023Research Squarepreprint
  19. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncologyconference-abstract
  20. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study2022Annals of Oncologyarticle
  21. 132TiP Dose escalation of chemoradiotherapy in locally advanced esophageal squamous cell carcinoma based on positron emission tomography response: A phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)2022Annals of Oncologyarticle
  22. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  23. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figsharedataset
  24. P-100 CXCL8 is a valid potential prognostical marker for esophageal squamous cell carcinoma2022Annals of Oncologyconference-abstract
  25. Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncologyconference-abstract
  26. Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncologyconference-abstract
  27. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncologyarticle
  28. 667 PEGYLATED RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR IN DEFINITIVE CHEMORADIOTHERAPY OF ESOPHAGEAL CANCER: PRELIMINARY RESULTS2021Diseases of the Esophagusarticle
  29. ASO Visual Abstract: Additional esophagectomy following noncurative endoscopic resection for early esophageal squamous cell carcinoma: a multicenter retrospective study2021Annals of Surgical Oncologyarticle
  30. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  31. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncologyconference-abstract
  32. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset
  33. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 54 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
54
2021–2025
Trials led
18
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 7720212022: 9920222023: 9920232024: 141420242025: 13132025

15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06812039

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 2 listed hospitals as study sitesFuzhou, Shanghai, Tianjin

  2. Recruiting
    Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2021-09
    Registry
    NCT05057845

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  3. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  4. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  5. Recruiting
    A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07376707

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  6. Not yet recruiting
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06779461

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsLocal treatment (ablation, TACE, HAIC)
Departments in papersMedical oncologyPathology / laboratory medicineRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led54
  1. ALKBH5 deficiency suppresses hepatocarcinogenesis in mice via m6A-dependent STAT1 restoration.2026Acta pharmacologica Sinica
  2. NRAV promotes HCC stemness via the m6A-regulated let-7c-5p/LIN28B axis.2026Cancer gene therapyFree full text
  3. LncRNA HOXC-AS1 Promotes Tumor Progression via miR-876-3p/NR3C1 in Hepatocellular Carcinoma.2025APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  4. A therapeutic strategy integrating ultrasound-guided microwave ablation with nanocomposite hydrogels to enhance autophagy and suppress tumor growth in hepatocellular carcinoma.2025Acta biomaterialia
  5. The liver-specific long noncoding RNA FAM99B inhibits ribosome biogenesis and cancer progression through cleavage of dead-box Helicase 21.2025Cell death & diseaseFree full text
  6. LTA4H improves the tumor microenvironment and prevents HCC progression via targeting the HNRNPA1/LTBP1/TGF-β axis.2025Cell reports. MedicineFree full text
  7. Efficacy of therapies for intermediate-stage hepatocellular carcinoma: systematic review and network meta-analysis.2025Frontiers in immunologyFree full text
  8. Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma.2025Human vaccines & immunotherapeuticsFree full text
  9. The Dichotomous Role of Tertiary Lymphoid Structures in Hepatocellular Carcinoma: From Spatial Location to Clinical Implications.2025Immunological investigations
  10. Circular RNA CDYL facilitates hepatocellular carcinoma stemness and PD-L1+ exosomes-mediated immunotherapy resistance via stabilizing hornerin protein by blocking synoviolin 1-mediated ubiquitination.2025International journal of biological macromolecules
  11. PD-1 suppresses human CD38+ circulating Tfr cells and regulates humoral immunity.2025Journal for immunotherapy of cancerFree full text
  12. Iodine-131 radioembolization boosts the immune activation enhanced by icaritin/resiquimod in hepatocellular carcinoma.2025Journal of controlled release : official journal of the Controlled Release Society
  13. SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming.2025Journal of experimental & clinical cancer research : CRFree full text
  14. Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy.2025Journal of hematology & oncologyFree full text
  15. Tumor-associated macrophage-based predictive and prognostic model for hepatocellular carcinoma.2025PloS oneFree full text
  16. Mutation-Selected Amplification droplet digital PCR: A new single nucleotide variant detection assay for TP53R249S mutant in tumor and plasma samples.2024Analytica chimica acta
  17. MicroRNA-148a-3p suppresses the glycolysis and Cell proliferation by targeting transmembrane protein 54 in liver cancer.2024Biochemical and biophysical research communications
  18. LTR retrotransposon-derived LncRNA LINC01446 promotes hepatocellular carcinoma progression and angiogenesis by regulating the SRPK2/SRSF1/VEGF axis.2024Cancer letters
  19. Hyperactivation of β-catenin signal in hepatocellular carcinoma recruits myeloid-derived suppressor cells through PF4-CXCR3 axis.2024Cancer letters
  20. Heat shock transcription factor 1 facilitates liver cancer progression by driving super-enhancer-mediated transcription of MYCN.2024Cancer medicineFree full text
  21. Metabolic self-feeding in HBV-associated hepatocarcinoma centered on feedback between circulation lipids and the cellular MAPK/mTOR axis.2024Cell communication and signaling : CCSFree full text
  22. Glucose-induced LINC01419 reprograms the glycolytic pathway by recruiting YBX1 to enhance PDK1 mRNA stability in hepatocellular carcinoma.2024Clinical and translational medicineFree full text
  23. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study.2024ESMO open
  24. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.2024Journal of hematology & oncologyFree full text
  25. Potent induction of antitumor immunity by combining cryo-thermal ablation with immune checkpoint inhibitors in hepatocellular carcinoma.2024Liver international : official journal of the International Association for the Study of the Liver
  26. Calpain 2 promotes Lenvatinib resistance and cancer stem cell traits via both proteolysis-dependent and independent approach in hepatocellular carcinoma.2024Molecular biomedicineFree full text
  27. Spatial single-cell protein landscape reveals vimentinhigh macrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma.2024Nature cancer
  28. Elevated choline drives KLF5-dominated transcriptional reprogramming to facilitate liver cancer progression.2024Oncogene
  29. Oncofetal TRIM71 drives liver cancer carcinogenesis through remodeling CEBPA-mediated serine/glycine metabolism.2024TheranosticsFree full text
  30. ASO Author Reflections: Early Recurrence in Hepatocellular Carcinoma Patients with Microvascular Invasion After Hepatectomy.2023Annals of surgical oncology
  31. A Practical Risk Classification of Early Recurrence in Hepatocellular Carcinoma Patients with Microvascular invasion after Hepatectomy: A Decision Tree Analysis.2023Annals of surgical oncology
  32. ZNF655 promotes the progression of hepatocellular carcinoma through PSMB8.2023Cell biology international
  33. TRIM14 Overexpression Induces Chemoresistance and Malignant Behaviors of Hepatocellular Carcinoma Cells by Activating the STAT3/HIF-1α Pathway.2023International journal of molecular sciencesFree full text
  34. Aberrantly expressed HIF-1α enhances HCC stem cell-like traits via Wnt/β-catenin signaling activation after insufficient radiofrequency ablation.2023Journal of cancer research and therapeutics
  35. Alcohol and the mechanisms of liver disease.2023Journal of gastroenterology and hepatology
  36. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers.2023Nature communicationsFree full text
  37. Bufalin Inhibits Tumorigenesis and SREBP-1-Mediated Lipogenesis in Hepatocellular Carcinoma via Modulating the ATP1A1/CA2 Axis.2023The American journal of Chinese medicine
  38. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study.2023The British journal of radiologyFree full text
  39. RNA binding protein RALY activates the cholesterol synthesis pathway through an MTA1 splicing switch in hepatocellular carcinoma.2022Cancer letters
  40. RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1.2022Cancer researchFree full text
  41. Endothelial Nogo-B Suppresses Cancer Cell Proliferation via a Paracrine TGF-β/Smad Signaling.2022CellsFree full text
  42. A pathway-guided strategy identifies a metabolic signature for prognosis prediction and precision therapy for hepatocellular carcinoma.2022Computers in biology and medicine
  43. Hepatic resection prolongs overall survival in the selected patients with nasopharyngeal carcinoma liver metastases.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  44. LncRNA-EWSAT1 promotes hepatocellular carcinoma metastasis via activation of the Src-YAP signaling axis.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  45. Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC.2022Hepatology international
  46. The value of preoperative 18F-FDG PET metabolic and volumetric parameters in predicting microvascular invasion and postoperative recurrence of hepatocellular carcinoma.2022Nuclear medicine communications
  47. Identification of a novel Calpain-2-SRC feed-back loop as necessity for β-Catenin accumulation and signaling activation in hepatocellular carcinoma.2022Oncogene
  48. Relative Quantification of N-Glycopeptide Sialic Acid Linkage Isomers by Ion Mobility Mass Spectrometry.2021Analytical chemistry
  49. Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma.2021BioengineeredFree full text
  50. Combinatorial Normalization of Liver-Derived Cytokine Pathways Alleviates Hepatic Tumor-Associated Cachexia in Zebrafish.2021Cancer research
  51. Gain of LINC00624 Enhances Liver Cancer Progression by Disrupting the Histone Deacetylase 6/Tripartite Motif Containing 28/Zinc Finger Protein 354C Corepressor Complex.2021Hepatology (Baltimore, Md.)
  52. Baseline apparent diffusion coefficients: Validation study of new predictor of survival in patients with unresectable hepatocellular carcinoma following chemoembolization.2021Journal of X-ray science and technology
  53. Identification of miRNAs, mRNAs, lncRNAs, and circRNAs associated with hepatocellular carcinoma recurrence after interferon treatment.2021Journal of biological regulators and homeostatic agents
  54. Comprehensive analysis of N6 -methyladenosine-related long non-coding RNAs for prognosis prediction in liver hepatocellular carcinoma.2021Journal of clinical laboratory analysisFree full text
Chinese-language papers (not in the count)1
  1. [The clinical value of serum GPC3 level in predicting recurrence of patients with primary hepatocellular carcinoma].2023Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
All its trials on ClinicalTrials.gov, any status45
  1. HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of RecurrenceRecruitingNCT06812039Lead (inferred)Phase 2Start 2025-01
  2. Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular CarcinomaRecruitingNCT05057845Lead (inferred)Phase 2Start 2021-09
  3. Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT06441019Lead (inferred)Phase 2Start 2024-07
  4. HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT06475287Lead (inferred)Phase 2Start 2024-07
  5. Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT06285019Lead (inferred)Phase 2Start 2023-12
  6. Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver MetastasesStatus unknownNCT05771025Lead (inferred)N/AStart 2023-04
  7. Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT05675462Lead (inferred)Phase 1Start 2023-03
  8. Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)Status unknownNCT05897268Lead (inferred)Phase 2Start 2023-06
  9. Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver TumorsStatus unknownNCT06588569Lead (inferred)N/AStart 2022-10
  10. Efficacy and Safety of T+A+RAD in HCCStatus unknownNCT05396937Lead (inferred)Phase 2Start 2022-01
  11. HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After ResectionStatus unknownNCT05311319Lead (inferred)Phase 2Start 2022-01
  12. TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)CompletedNCT04954794Lead (inferred)Phase 2Start 2021-07
  13. Tislelizumab in the Systematic Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04996459Lead (inferred)Start 2020-03
  14. TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular CarcinomaCompletedNCT04297280Lead (inferred)Phase 2Start 2020-04
  15. ALPPS Combined With Tislelizumab in Liver MalignancyStatus unknownNCT04996446Lead (inferred)Phase 2Start 2020-08
  16. Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPaseStatus unknownNCT01715532Lead (inferred)Phase 2Start 2012-07
  17. Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver CancerStatus unknownNCT00999843Lead (inferred)Phase 1/Phase 2Start 2009-10
  18. Songyou Granule and Transarterial Chemoembolization for Hepatocellular CarcinomaStatus unknownNCT00805896Lead (inferred)Phase 2Start 2008-12
  19. A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid TumorsRecruitingNCT07376707Study sitePhase 1Start 2025-06
  20. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  21. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  22. A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular CarcinomaNot yet recruitingNCT06779461Study sitePhase 3Start 2025-01
  23. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  24. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  25. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  26. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver CancerTerminatedNCT04520906Study siteN/AStart 2020-12
  27. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Study sitePhase 1/Phase 2Start 2019-07
  28. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  29. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  30. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  31. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  32. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  33. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  34. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  35. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  36. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  37. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  38. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
  39. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09
  40. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Study sitePhase 2Start 2017-05
  41. A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Study sitePhase 2Start 2016-11
  42. Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02953743Study sitePhase 1Start 2016-09
  43. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaCompletedNCT02508467Study sitePhase 1Start 2015-07
  44. Efficacy and Safety Study of TLC388 to Advanced Hepatocellular CarcinomaTerminatedNCT02267213Study sitePhase 2Start 2014-04
  45. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Study sitePhase 1/Phase 2Start 2014-01

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 88 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.9%.

Papers led
88
2021–2025
Trials led
44
any status, ClinicalTrials.gov
Open trials led
17
recruiting or about to
Open trials as a site
21
led by another institution
Papers led per year
2021: 171720212022: 171720222023: 151520232024: 191920242025: 20202025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 38

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07492615

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  2. Recruiting
    Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07517107

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  3. Recruiting
    Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07194005

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  4. Recruiting
    The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07757165

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  5. Recruiting
    Metronomic Capecitabine in Stage III Gastric Cancer
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06313567

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  6. Recruiting
    The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06786169

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  7. Recruiting
    The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT07400354

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  8. Recruiting
    Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
    Phase
    Phase 2
    Started
    2023-01
    Registry
    NCT05975749

    Age 20 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  9. Recruiting
    Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
    Phase
    Phase 2
    Started
    2023-01
    Registry
    NCT06121700

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  10. Recruiting
    A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
    Phase
    N/A
    Started
    2023-11
    Registry
    NCT06158919

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  11. Recruiting
    Laparoscopic vs Open Total Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2022-10
    Registry
    NCT05537129

    Age 20 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  12. Recruiting
    Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer
    Phase
    Not given
    Started
    2021-05
    Registry
    NCT04809025

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  13. Recruiting
    Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04997837

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  14. Not yet recruiting
    A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07878221

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  15. Not yet recruiting
    Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07912957

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  16. Not yet recruiting
    Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06748508

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  17. Enrolling by invitation
    Anemia on Sublingual Microcirculation in GDFT
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07583927

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  18. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  19. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  20. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  21. Recruiting
    A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06760819

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai

  22. Recruiting
    HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06769425

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  23. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  24. Recruiting
    Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07366528

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin Hospital; 3 listed hospitals as study sitesShanghai

  25. Recruiting
    A IIT Study of 177Lu-DOTA-SNA040
    Phase
    Early phase 1
    Started
    2025-11
    Registry
    NCT07595237

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  26. Recruiting
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06128252

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an

  27. Recruiting
    Early Detection and Post-operative Monitoring of Gastric Cancer
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06232395

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  28. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  29. Recruiting
    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06469944

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Urumqi, Xiamen, Zhengzhou

  30. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  31. Recruiting
    Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06679244

    Age 18 years to 80 years (registered criteria)

    Led by Huashan Hospital; 2 listed hospitals as study sitesShanghai

  32. Recruiting
    Post-operative Monitoring of Gastric Cancer
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT07026240

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  33. Recruiting
    A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT07923214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Fuzhou, Shanghai

  34. Recruiting
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06081647

    Age 18 years to 60 years (registered criteria)

    Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai

  35. Recruiting
    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-11
    Registry
    NCT06131840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  36. Not yet recruiting
    TR115 in ARID1A-Mutated Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07793318

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  37. Not yet recruiting
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07902596

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou

  38. Not yet recruiting
    A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07036185

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsPeritoneal spread & advanced diseaseSurgery
Departments in papersMedical oncologyPathology / laboratory medicineRadiation oncologyRadiology / nuclear medicine
Papers it led88
  1. Exosomal CCT6A Secreted by Cancer-Associated Fibroblasts Interacts with β-Catenin to Enhance Chemoresistance and Tumorigenesis in Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Comparative genomic analysis of Helicobacter pylori isolates from gastric cancer and gastritis in China.2025BMC cancerFree full text
  3. Artifact reduction and diagnostic value of monoenergetic reconstructions from split-filter and dual-layer spectral detector dual-energy CT in early gastric cancer with titanium clip localization.2025BMC medical imagingFree full text
  4. FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity.2025Cancer letters
  5. PDPN+LTBP1+ cancer-associated fibroblasts induce a liver pre-metastatic niche in gastric cancer via PDPN/YAP/LTBP1 and CCL11/CCR3 axis.2025Cell communication and signaling : CCSFree full text
  6. An EBNA1-YAP signaling axis drives immune escape through CD276 in EBV-associated gastric cancer.2025Cell death & diseaseFree full text
  7. The value of serum tumor-associated autoantibodies in screening and diagnosis of gastric cancer.2025Clinica chimica acta; international journal of clinical chemistry
  8. Development and validation of a gastric cancer prognostic model utilizing lymphatic endothelial cell-related genes.2025Diagnostic pathologyFree full text
  9. Optimizing surgical timing following neoadjuvant therapy for gastric Cancer: Insights from a multicenter retrospective analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01).2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationRCT
  11. Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models.2025International journal of nanomedicineFree full text
  12. Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset gastric cancer: A retrospective cohort study.2025Journal of advanced researchFree full text
  13. Helicobacter pylori and gastric cancer: mechanisms and new perspectives.2025Journal of hematology & oncologyFree full text
  14. Preclinical Evaluation of 68Ga-Labeled CSPG4-Targeting Peptides for PET/CT Imaging in Pancreatic and Gastric Carcinoma.2025Journal of medicinal chemistryFree full text
  15. BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer.2025Molecular cancerFree full text
  16. A nucleotide regulates NR4A1 status in gastric cancer.2025Molecular cell
  17. Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response.2025Nature communicationsFree full text
  18. Effects of Oral Nutritional Supplements in Gastric Cancer Patients with Malnutrition-Sarcopenia Syndrome.2025Nutrition and cancer
  19. USP14-IMP2-CXCL2 axis in tumor-associated macrophages facilitates resistance to anti-PD-1 therapy in gastric cancer by recruiting myeloid-derived suppressor cells.2025Oncogene
  20. An inherited predisposition allele promotes gastric cancer via enhancing deubiquitination-mediated activation of epithelial-to-mesenchymal transition signaling.2025The Journal of clinical investigationFree full text
  21. Gastric point-of-care ultrasonography in patients undergoing radical gastrointestinal surgery before anesthetic induction: an observational cohort study.2024BMC anesthesiologyFree full text
  22. CC chemokine receptors are prognostic indicators of gastric cancer and are associated with immune infiltration.2024BMC medical genomicsFree full text
  23. Single cell and bulk RNA sequencing identifies tumor microenvironment subtypes and chemoresistance-related IGF1+ cancer-associated fibroblast in gastric cancer.2024Biochimica et biophysica acta. Molecular basis of disease
  24. LncRNA-CCAT5-mediated crosstalk between Wnt/β-Catenin and STAT3 signaling suggests novel therapeutic approaches for metastatic gastric cancer with high Wnt activity.2024Cancer communications (London, England)Free full text
  25. SNHG15-mediated feedback loop interplays with HNRNPA1/SLC7A11/GPX4 pathway to promote gastric cancer progression.2024Cancer scienceFree full text
  26. LncRNA SNHG26 promotes gastric cancer progression and metastasis by inducing c-Myc protein translation and an energy metabolism positive feedback loop.2024Cell death & diseaseFree full text
  27. Immunosuppressive MFAP2+ cancer associated fibroblasts conferred unfavorable prognosis and therapeutic resistance in gastric cancer.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  28. Systematic Analysis of Tumor Stem Cell-related Gene Characteristics to Predict the PD-L1 Immunotherapy and Prognosis of Gastric Cancer.2024Current medicinal chemistry
  29. The distribution and maturation of tertiary lymphoid structures can predict clinical outcomes of patients with gastric adenocarcinoma.2024Frontiers in immunologyFree full text
  30. Remote modulation of WWOX by an intronic variant associated with survival of Chinese gastric cancer patients.2024International journal of cancer
  31. Finding the minimum number of retrieved lymph nodes and negative lymph nodes in gastric cancer surgery: a real-world study.2024International journal of surgery (London, England)Free full text
  32. Clinical comparison of total gastrectomy with single-vessel transection Roux-en-Y reconstruction vs total gastrectomy with conventional Roux-en-Y reconstruction for proximal gastric cancer.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  33. Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer.2024Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  34. C3+ cancer-associated fibroblasts promote tumor growth and therapeutic resistance in gastric cancer via activation of the NF-κB signaling pathway.2024Journal of translational medicineFree full text
  35. Targeting SOX13 inhibits assembly of respiratory chain supercomplexes to overcome ferroptosis resistance in gastric cancer.2024Nature communicationsFree full text
  36. CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage.2024OncoimmunologyFree full text
  37. Assessing the Value of 68Ga-FAPI PET/CT in Gastric Mucinous Adenocarcinoma or Signet Ring Cell Carcinoma.2024Radiology. Imaging cancerFree full text
  38. Low-dose radiotherapy synergizes with iRGD-antiCD3-modified T cells by facilitating T cell infiltration.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  39. Identifying an immunosenescence-associated gene signature in gastric cancer by integrating bulk and single-cell sequencing data.2024Scientific reportsFree full text
  40. Calcipotriol abrogates cancer-associated fibroblast-derived IL-8-mediated oxaliplatin resistance in gastric cancer cells via blocking PI3K/Akt signaling.2023Acta pharmacologica SinicaFree full text
  41. Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial.2023Cancer biology & medicineRCTFree full text
  42. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.2023Cancer immunology, immunotherapy : CIIFree full text
  43. Comprehensive analysis of immune subtypes reveals the prognostic value of cytotoxicity and FAP+ fibroblasts in stomach adenocarcinoma.2023Cancer immunology, immunotherapy : CIIFree full text
  44. ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer.2023Cancer medicineFree full text
  45. Partial omentectomy maybe practicable for T3 or shallower gastric cancer patients.2023Cancer medicineFree full text
  46. Construction of ovarian metastasis-related immune signature predicting prognosis of gastric cancer patients.2023Cancer medicineFree full text
  47. CD47-targeted immunotherapy unleashes antitumour immunity in Epstein-Barr virus-associated gastric cancer.2023Clinical immunology (Orlando, Fla.)
  48. Novel biogenic preparation of gold nanoparticles decorated on sepiolite clay and evaluation of anti-cancer effect on gastric cancer cell and electrochemical sensing of nitrite.2023Environmental research
  49. Multi-dimension metabolic prognostic model for gastric cancer.2023Frontiers in endocrinologyFree full text
  50. SDC2 Stabilization by USP14 Promotes Gastric Cancer Progression through Co-option of PDK1.2023International journal of biological sciencesFree full text
  51. Tumor-infiltrating CD226+CD8+ T cells are associated with postoperative prognosis and adjuvant chemotherapeutic benefits in gastric cancer patients.2023Journal of cancer research and clinical oncologyFree full text
  52. Hsa_circ_0001944 enhanced GSPT1 expression via sponging miR-498 to promote proliferation and invasion of gastric cancer.2023Journal of clinical laboratory analysisFree full text
  53. Periostin secreted from podoplanin-positive cancer-associated fibroblasts promotes metastasis of gastric cancer by regulating cancer stem cells via AKT and YAP signaling pathway.2023Molecular carcinogenesis
  54. The epigenetic modifier lysine methyltransferase 2C is frequently mutated in gastric remnant carcinoma.2023The journal of pathology. Clinical researchFree full text
  55. CPT1C promotes the potential of gastric cancer ovarian metastasis through up-regulating fatty acid oxidation.2022Acta biochimica et biophysica SinicaFree full text
  56. Usefulness of endoscopic ultrasound for acquiring the pathological diagnosis of gastrointestinal lymphoma.2022Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  57. Multiplexed immunofluorescence analysis of CAF-markers, EZH2 and FOXM1 in gastric tissue: associations with clinicopathological parameters and clinical outcomes.2022BMC cancerFree full text
  58. A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma:2022BMC cancerFree full text
  59. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).2022Cancer communications (London, England)RCTFree full text
  60. The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer.2022Cell death & diseaseFree full text
  61. Integrated DNA and RNA sequencing reveals early drivers involved in metastasis of gastric cancer.2022Cell death & diseaseFree full text
  62. Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer.2022Clinical immunology (Orlando, Fla.)
  63. Activation of MAT2A-ACSL3 pathway protects cells from ferroptosis in gastric cancer.2022Free radical biology & medicine
  64. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.2022Frontiers in immunologyFree full text
  65. Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer.2022Frontiers in immunologyFree full text
  66. Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer.2022Frontiers in immunologyFree full text
  67. How Can We Better Understand the Gastric Carcinogenesis of Helicobacter pylori?2022Gastroenterology
  68. ASTE1 frameshift mutation triggers the immune response in Epstein-Barr virus-associated gastric cancer.2022Signal transduction and targeted therapyFree full text
  69. The role of nutritional assessment for predicting radiotherapy-induced adverse events in patients with gastric cancer.2022The British journal of radiologyFree full text
  70. Novel management indications for conservative treatment of chylous ascites after gastric cancer surgery.2022World journal of gastroenterologyFree full text
  71. Prognostic significance of tumor deposits in radically resected gastric cancer: a retrospective study of a cohort of 1915 Chinese individuals.2022World journal of surgical oncologyFree full text
  72. Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1.2021Acta biochimica et biophysica Sinica
  73. Combined chemotherapy of platinum and fluorouracil promotes T cell-mediated antitumor immunity.2021Acta biochimica et biophysica Sinica
  74. The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy.2021BMC cancerFree full text
  75. Crocetin suppresses angiogenesis and metastasis through inhibiting sonic hedgehog signaling pathway in gastric cancer.2021Biochemical and biophysical research communications
  76. Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy.2021Cancer immunology, immunotherapy : CIIFree full text
  77. Short-form RON (sf-RON) enhances glucose metabolism to promote cell proliferation via activating β-catenin/SIX1 signaling pathway in gastric cancer.2021Cell biology and toxicologyFree full text
  78. Value of staging information provided by linear-array endoscopic ultrasound for therapeutic response and prognosis prediction in gastric lymphoma.2021Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  79. Letter to editor: development and internal validation of a diagnostic score for gastric linitis plastic.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  80. Circ-PTPDC1 promotes the Progression of Gastric Cancer through Sponging Mir-139-3p by Regulating ELK1 and Functions as a Prognostic Biomarker.2021International journal of biological sciencesFree full text
  81. Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer.2021Journal for immunotherapy of cancerFree full text
  82. NTF4 stimulates the progression of gastric cancer via regulating FOXL1.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  83. Cation Lipid-Assisted PEG6-PLGA Polymer Nanoparticles Encapsulated Knocking Down Long ncRNAs Reverse Non-Coding RNA of Xist Through the Support Vector Machine Model to Regulate the Molecular Mechanisms of Gastric Cancer Cell Apoptosis.2021Journal of biomedical nanotechnology
  84. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.2021Journal of cancer research and clinical oncologyFree full text
  85. Involvement of APRIL in Helicobacter pylori-related gastric cancer.2021Journal of cancer research and clinical oncologyFree full text
  86. miR-504 Promoted Gastric Cancer Cell Proliferation and Inhibited Cell Apoptosis by Targeting RBM4.2021Journal of immunology researchFree full text
  87. Three-year outcomes of the randomized phase III SEIPLUS trial of extensive intraoperative peritoneal lavage for locally advanced gastric cancer.2021Nature communicationsRCTFree full text
  88. Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer.2021Nature communicationsFree full text
Chinese-language papers (not in the count)11
  1. [Application and challenges of neoadjuvant therapy in gastric cancer in the immunotherapy era].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Analysis of the safety and efficacy of neoadjuvant immunotherapy combined with chemotherapy for radical resection of locally advanced gastric cancer: a two-center propensity-matched study].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Minimum negative lymph node dissection during radical gastrectomy for gastric cancer: a 22-year, single-center retrospective study].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Rethinking lymph node dissection in gastric cancer during the era of immunotherapy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Analysis of age cut-off and prognosis of early-onset gastric cancer in young patients].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Interpretation of Chinese expert consensus on function-preserving grstrectomy for gastric cancer(2025 edition)].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  8. [Significance and treatment strategies of pathologic complete response after neoadjuvant therapy for gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Analysis on perioperative safety and feasibility of pure single-port laparoscopic distal gastrectomy for gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [The diagnosis and treatment of G3 neuroendocrine tumors according to the new NCCN guideline].2022Zhonghua yi xue za zhi
  11. [Gastric SWI/SNF-complex deficient undifferentiated/rhabdoid carcinoma: a clinicopathological study].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status97
  1. PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant ChemotherapyCompletedNCT03013010Lead sponsorPhase 3Start 2016-12
  2. A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT07492615Lead (inferred)Phase 2Start 2026-01
  3. Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJNot yet recruitingNCT07912957Lead (inferred)Phase 2Start 2026-11
  4. Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric CancerRecruitingNCT07517107Lead (inferred)Phase 2Start 2026-01
  5. Anemia on Sublingual Microcirculation in GDFTEnrolling by invitationNCT07583927Lead (inferred)Start 2026-05
  6. A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction CancerNot yet recruitingNCT07878221Lead (inferred)Phase 2Start 2026-10
  7. Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric CancerRecruitingNCT07194005Lead (inferred)Phase 2Start 2025-09
  8. The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion TherapyRecruitingNCT07757165Lead (inferred)Phase 2Start 2025-11
  9. The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric CancerRecruitingNCT06786169Lead (inferred)Start 2024-09
  10. The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut MicrobiotaRecruitingNCT07400354Lead (inferred)Start 2024-03
  11. Metronomic Capecitabine in Stage III Gastric CancerRecruitingNCT06313567Lead (inferred)Phase 3Start 2024-03
  12. Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric CancerNot yet recruitingNCT06748508Lead (inferred)Phase 2Start 2024-12
  13. Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric CancerRecruitingNCT05975749Lead (inferred)Phase 2Start 2023-01
  14. Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ CancerRecruitingNCT06121700Lead (inferred)Phase 2Start 2023-01
  15. A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ CancerRecruitingNCT06158919Lead (inferred)N/AStart 2023-11
  16. Laparoscopic vs Open Total Gastrectomy for Gastric CancerRecruitingNCT05537129Lead (inferred)N/AStart 2022-10
  17. Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric CancerRecruitingNCT04809025Lead (inferred)Start 2021-05
  18. Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ AdenocarcinomaRecruitingNCT04997837Lead (inferred)Phase 3Start 2021-07
  19. Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06914687Lead (inferred)Phase 2Start 2025-04
  20. Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric CancerActive, not recruitingNCT07312500Lead (inferred)Start 2025-01
  21. Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric AdenocarcinomaSuspendedNCT06728657Lead (inferred)Phase 2Start 2024-07
  22. Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06447636Lead (inferred)Phase 2Start 2024-09
  23. Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGCStatus unknownNCT05982834Lead (inferred)Phase 1/Phase 2Start 2023-05
  24. Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)Status unknownNCT05893056Lead (inferred)Phase 2Start 2023-06
  25. Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric CancerStatus unknownNCT05982301Lead (inferred)Phase 2Start 2023-02
  26. Laparoscopic-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric CancerCompletedNCT05541783Lead (inferred)N/AStart 2022-09
  27. Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric CancerTerminatedNCT05161572Lead (inferred)Phase 2Start 2021-09
  28. Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric CancerStatus unknownNCT05095636Lead (inferred)Phase 2Start 2021-03
  29. Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus unknownNCT05111444Lead (inferred)Phase 2Start 2021-12
  30. A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant AscitesStatus unknownNCT03475615Lead (inferred)Phase 3Start 2018-03
  31. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)CompletedNCT03399110Lead (inferred)Phase 3Start 2018-01
  32. The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric CancerCompletedNCT02395640Lead (inferred)Phase 3Start 2015-03
  33. Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric CancerStatus unknownNCT02072317Lead (inferred)Phase 2Start 2013-11
  34. Neoadjuvant Chemotherapy Plus Chemoradiation in Patients With Potentially Resectable Gastric CarcinomaStatus unknownNCT02024217Lead (inferred)Phase 2Start 2012-03
  35. Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Quality of Life in Patients Undergoing Total GastrectomyStatus unknownNCT01697943Lead (inferred)Phase 3Start 2012-05
  36. A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGCStatus unknownNCT01963702Lead (inferred)Phase 2Start 2012-08
  37. Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric CancerCompletedNCT00970138Lead (inferred)Phase 2/Phase 3Start 2009-06
  38. Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric CancerStatus unknownNCT00992199Lead (inferred)Phase 2Start 2009-08
  39. Study of Cetuximab to Treat Gastric CancerCompletedNCT00699881Lead (inferred)Phase 2Start 2008-05
  40. Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric CancerSuspendedNCT00568529Lead (inferred)Phase 2Start 2007-10
  41. Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric CancerTerminatedNCT00595985Lead (inferred)Phase 2Start 2007-07
  42. Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric CancerCompletedNCT00595972Lead (inferred)Phase 2Start 2007-11
  43. Study of Weekly DCF to Treat Advanced Gastric CancerTerminatedNCT00568971Lead (inferred)Phase 2Start 2007-04
  44. Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGCCompletedNCT00767377Lead (inferred)Phase 2Start 2007-05
  45. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  46. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  47. TR115 in ARID1A-Mutated Advanced Solid TumorsNot yet recruitingNCT07793318Study sitePhase 2Start 2026-09
  48. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ AdenocarcinomaNot yet recruitingNCT07902596Study siteStart 2026-10
  49. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  50. A IIT Study of 177Lu-DOTA-SNA040RecruitingNCT07595237Study siteEarly phase 1Start 2025-11
  51. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Study sitePhase 2Start 2025-02
  52. A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid TumorsNot yet recruitingNCT07036185Study sitePhase 1Start 2025-06
  53. HS-10502 Combination Treatment in Patients With Advanced Solid TumorsRecruitingNCT06769425Study sitePhase 1Start 2025-05
  54. Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric CancerRecruitingNCT07366528Study sitePhase 3Start 2025-12
  55. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  56. Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled StudyRecruitingNCT06679244Study siteN/AStart 2024-12
  57. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  58. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingNCT06324357Study sitePhase 1/Phase 2Start 2024-06
  59. Early Detection and Post-operative Monitoring of Gastric CancerRecruitingNCT06232395Study siteStart 2024-02
  60. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNCT06128252Study siteN/AStart 2024-09
  61. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingNCT06469944Study sitePhase 1/Phase 2Start 2024-09
  62. A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsRecruitingNCT07923214Study sitePhase 1Start 2024-07
  63. Post-operative Monitoring of Gastric CancerRecruitingNCT07026240Study siteStart 2024-02
  64. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy ProcedureRecruitingNCT06081647Study siteN/AStart 2023-12
  65. A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsRecruitingNCT06131840Study sitePhase 1Start 2023-11
  66. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  67. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.Active, not recruitingNCT06116136Study sitePhase 1/Phase 2Start 2024-08
  68. EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung CancerWithdrawnNCT05411679Study sitePhase 2Start 2023-04
  69. HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric CancerStatus unknownNCT05246982Study sitePhase 2Start 2022-03
  70. Development of Free DNA Multi-target Methylated PCR for Auxiliary Diagnosis of Gastric CancerCompletedNCT05336058Study siteStart 2022-02
  71. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  72. IMM2902 in Patients With Advanced Solid Tumors Expressing HER2Status unknownNCT05805956Study sitePhase 1/Phase 2Start 2022-02
  73. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  74. Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)Active, not recruitingNCT05382364Study sitePhase 1Start 2022-06
  75. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  76. Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSEActive, not recruitingNCT04919226Study sitePhase 3Start 2021-12
  77. SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System MalignanciesTerminatedNCT05039944Study sitePhase 2Start 2021-11
  78. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  79. A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.Status unknownNCT04435652Study sitePhase 2/Phase 3Start 2020-07
  80. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  81. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  82. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  83. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  84. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  85. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  86. Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric CancerCompletedNCT03619681Study sitePhase 1Start 2018-09
  87. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  88. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
  89. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  90. A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric CancerCompletedNCT02426034Study sitePhase 4Start 2015-05
  91. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  92. A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric CancerCompletedNCT02252913Study sitePhase 1Start 2014-09
  93. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  94. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  95. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  96. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09
  97. Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric CancerCompletedNCT01512745Study sitePhase 3Start 2011-01

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 3 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 2.9%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 002025

15 hospitals in Shanghai for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 2220242025: 112025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led6
  1. Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas.2025Biomolecules
  2. Osteosarcoma-targeted Cu and Ce based oxide nanoplatform for NIR II fluorescence/magnetic resonance dual-mode imaging and ros cascade amplification along with immunotherapy.2024Journal of nanobiotechnology
  3. Gastrointestinal Ewing Sarcoma: A Clinicopathological and Molecular Genetic Analysis of 25 Cases.2024The American journal of surgical pathology
  4. Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis ?2023European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  5. LncRNA-EWSAT1 promotes hepatocellular carcinoma metastasis via activation of the Src-YAP signaling axis.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  6. KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.2021Biochemical and biophysical research communications
Earlier papers (2016–2020)7
  1. Growth hormone receptor promotes osteosarcoma cell growth and metastases.2020FEBS open bio
  2. Silencing of synaptotagmin 7 regulates osteosarcoma cell proliferation, apoptosis, and migration.2020Histology and histopathology
  3. Metabolism of Reactive Oxygen Species in Osteosarcoma and Potential Treatment Applications.2019Cells
  4. Knockdown of Kinesin Family 15 Inhibits Osteosarcoma through Suppressing Cell Proliferation and Promoting Cell Apoptosis.2019Chemotherapy
  5. Oridonin inhibits the proliferation, migration and invasion of human osteosarcoma cells via suppression of matrix metalloproteinase expression and STAT3 signalling pathway.2019Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  6. HOTAIR promotes osteosarcoma development by sponging miR-217 and targeting ZEB1.2019Journal of cellular physiology
  7. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.2018European journal of pharmacology

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

  2. Recruiting
    A Study of HQP1351 in Patients With GIST or Other Solid Tumors
    Phase
    Phase 1
    Started
    2018-07
    Registry
    NCT03594422

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)6
  1. Development and validation of a nomogram based on CT images and 3D texture analysis for preoperative prediction of the malignant potential in gastrointestinal stromal tumors.2020Cancer imaging : the official publication of the International Cancer Imaging Society
  2. A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.2020Cancer medicine
  3. Gastric sub-epithelial tumors: identification of gastrointestinal stromal tumors using CT with a practical scoring method.2019Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  4. Differentiation of Gastric Schwannoma From Gastric Gastrointestinal Stromal Tumor With Dual-Phase Contrast-Enhanced Computed Tomography.2019Journal of computer assisted tomography
  5. MiR-374b Promotes Proliferation and Inhibits Apoptosis of Human GIST Cells by Inhibiting PTEN through Activation of the PI3K/Akt Pathway.2018Molecules and cells
  6. Involvement of Bmi-1 gene in the development of gastrointestinal stromal tumor by regulating p16Ink4A/p14ARF gene expressions: An in vivo and in vitro study.2017Pathology, research and practice
All its trials on ClinicalTrials.gov, any status7
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Study sitePhase 1Start 2018-07
  3. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Study sitePhase 2Start 2020-04
  4. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  5. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08
  6. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03
  7. A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTStatus unknownNCT02776878Study siteN/AStart 2016-05

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 4 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 2.5%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine
Papers it led4
  1. Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas.2025Biomolecules
  2. Gastrointestinal Ewing Sarcoma: A Clinicopathological and Molecular Genetic Analysis of 25 Cases.2024The American journal of surgical pathology
  3. Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis ?2023European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  4. LncRNA-EWSAT1 promotes hepatocellular carcinoma metastasis via activation of the Src-YAP signaling axis.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
All its trials on ClinicalTrials.gov, any status1
  1. Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)TerminatedNCT00568464Lead (inferred)Phase 2Start 2007-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

9 hospitals in Shanghai for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06445803

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanchang, Shanghai

  2. Recruiting
    Phase Ib Clinical Study of Keynatinib
    Phase
    Phase 1
    Started
    2020-09
    Registry
    NCT04807881

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHLRecruitingNCT06445803Study sitePhase 1Start 2024-05
  2. Phase Ib Clinical Study of KeynatinibRecruitingNCT04807881Study sitePhase 1Start 2020-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

9 hospitals in Shanghai for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. A one-stop approach to diagnosing hereditary colorectal cancer in the Chinese population.2023Journal of gastroenterology and hepatology
Chinese-language papers (not in the count)1
  1. [A case of familial adenomatous polyposis in an adult male with Lynch-like syndrome].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Earlier papers (2016–2020)1
  1. [Advance in research on the correlation between genotypes of susceptible mutations and clinical phenotype of familial adenomatous polyposis].2017Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

复旦大学附属肿瘤医院

Fudan University Shanghai Cancer Center

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Shanghai Cancer Center; Fudan University Cancer Hospital; Fudan University Shanghai Cancer Centre; Fudan University Shanghai Cancer Centers; Fudan University Shanghai Cancer Center Xiamen Hospital; Cancer Hospital of Fudan University; Shanghai Cancer Hospital; and Fudan University Shanghai Cancer Center

Suggest a correctionDownload the data